Their latest funding was raised on Jun 22, 2022 from a Post-IPO Equity round. Numerous ASMs are available for the treatment of focal seizures in the U.S. These U.S. patents are expected to expire in 2040 and 2039, respectively, absent any extensions of patent term. Xenon Pharmaceuticals (NASDAQ:XENE) - a biopharmaceutical company with operations in Vancouver, BC, Canada and Boston, MA, U.S.A. - is committed to delivering innovative medicines to provide a. Greater Boston, primarily Boston and Cambridge, is home to almost 1,000 biotechnology companies, ranging from small start-ups to billion-dollar pharmaceutical companies. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Cash and cash equivalents and marketable securities as of December 31, 2021 were $551.8 million, compared to $177.0 million as of December 31, 2020. In addition, the ongoing X-TOLE open-label extension also continues to generate important long-term data for XEN1101 in FOS. The many universities in the area give the region a large network of scientists. XEN1101XEN1101 is a differentiated Kv7 potassium channel opener being developed for the treatment of epilepsy and major depressive disorder (MDD). These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events, or developments to be materially different from those expressed or implied by such forward-looking statements. BURNABY, British Columbia, June 27, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing of its previously . These forward-looking statements are not based on historical fact, and include statements regarding the timing of and results from clinical trials and pre-clinical development activities, including those related to XEN496, XEN1101, and other proprietary products, and those related to NBI-921352, PCRX301, and other partnered product candidates; the potential efficacy, safety profile, future development plans, addressable market, regulatory success and commercial potential of XEN496, XEN1101 and other proprietary and partnered product candidates; the anticipated timing of IND, or IND-equivalent, submissions and the initiation of future clinical trials for XEN496, XEN1101, and other proprietary products, and those related to NBI-921352, PCRX301, and other partnered candidates; the efficacy of our clinical trial designs; our ability to successfully develop and achieve milestones in the XEN496, XEN1101, and other proprietary development programs; the timing and results of our interactions with regulators; anticipated enrollment in our clinical trials and the timing thereof; the progress and potential of our other ongoing development programs; the potential receipt of milestone payments and royalties from our collaborators; our expectation of having sufficient cash to fund operations into at least 2024; our efforts to enhance our intellectual property portfolio; the timing of potential publication or presentation of future clinical data; and the sale of any common shares pursuant to the at-the-market equity offering, including the price, volume and timing of any distributions. The change was primarily attributable to higher research and development and general and administrative expenses, and lower revenue as compared to the same period in 2020. Xenon Pharmaceuticals Advancing a novel product pipeline of neurology therapies View Product Pipeline About We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. They are registered in the United States and used or registered in various other jurisdictions. Road, INDORE - 452001 (M.P). Our U.S. Company (Xenon Pharmaceuticals USA Inc.) is based in the Boston area. Xenon Pharma PVT. As was the case in the DBP, two AEs of urinary retention occurred in the OLE possibly related to study drug; both patients continued in the study without requiring intervention. Our novel product pipeline of neurology therapies addresses areas of high unmet medical need, with a focus on epilepsy. Jefferies, J.P. Morgan, SVB Securities and Stifel acted as joint book-running managers for the offering. The topline data showed all primary and secondary seizure reduction endpoints were statistically significant across all dose groups, including the primary endpoint of median reduction from baseline in monthly seizure frequency and in the key secondary endpoint of patients with at least a 50% reduction in monthly focal seizure frequency from baseline, with p-values of <0.001 for both the 20 mg and 25 mg dose groups. Design & Developed by Hivends Info Solutions. Follow Us: 01662-246253, 246252 | 94160-45111,89015-46111, 98963-50359 | Send Us Enquiry. 1 min read. Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. Xenon Pharmaceuticals Financials Summary financials Revenue ( Q2, 2022) $536.0K Gross profit ( Q2, 2022) $536.0K Net income ( Q2, 2022) ($31.2M) Cash ( Q2, 2022) $370.0M EBIT ( Q2, 2022) ($31.6M) Enterprise value $1.7B Competitors and similar companies China Medical System Healthcare - Public ReCept Pharmacy Healthcare - Private ELC Group Fax: 604.484.3450 The increase of $9.0 million was primarily attributable to increased salaries and benefits from additional headcount, stock-based compensation expense, market research costs and legal fees for intellectual property protection. It Offers High Quality Products With Attractive Packing, Reasonable Prices And Dedicated Service Focussed On Eye & ENT Care. Research and development expenses for the year ended December 31, 2021 were $75.5 million, compared to $50.5 million for the same period in 2020. You can contact us for more details call us:+91 9310577789. XENON PHARMACEUTICALS INC.Condensed Consolidated Balance Sheets(Expressed in thousands of U.S. dollars), Cash and cash equivalents and marketable securities, Total liabilities and shareholders equity, XENON PHARMACEUTICALS INC.Condensed Consolidated Statements of Operations(Expressed in thousands of U.S. dollars except share and per share amounts), Net loss attributable to preferred shareholders, Net loss attributable to common shareholders. : 01662-246253, 246252. Xenon also announced today that it has amended its at-the-market equity offering sales agreement dated August 6, 2020, with Jefferies LLC and Stifel, Nicolaus & Company, Incorporated, under which Xenon may sell its common shares from time-to-time. Xenon Pharmaceuticals Is An Ethical Pharma Company. Previously, in May 2022, Xenon announced its plans to evaluate XEN1101 as a treatment for Major Depressive Disorder (MDD). Additionally, alignment was obtained with the FDA on key elements of a single Phase 3 clinical trial to pursue an additional epilepsy indication of primary generalized tonic clonic seizures (PGTCS). We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. At Week 1, the median percent reduction in monthly focal onset seizure frequency was 55.4% in the 25 mg group (p<0.001), 41.5% in the 20 mg group (p=0.039), and 39.1% in the 10 mg group (p=0.002) compared to 20.2% in the placebo group. LTD. is the best pharmaceutical company in India. Currency in USD Follow 2W 10W 9M 36.77. INDIA In This Endeavour, XENON Pharmaceuticals Offers Antibacterial, Antiallergics, Steroids, Anti-Oxidants, Etc. Additional primary and secondary measures included a pairwise comparison of each active dose to placebo and a responder analysis with the proportion of patients who achieved a 50% or greater reduction in monthly focal seizure frequency from baseline. Xenon continues to execute on its comprehensive strategy to protect and expand the intellectual property portfolio that covers XEN1101. BURNABY, British Columbia, March 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the year ended December 31, 2021 and provided a corporate update. Approximately 360 patients will be randomized 1:1:1 for once-daily dosing of XEN1101 (15 mg), XEN1101 (25 mg) or placebo in each trial. Xenon has initiated its XEN1101 Phase 3 development program, which includes two identical Phase 3 clinical trials called X-TOLE2 and X-TOLE3, which are designed closely after the Phase 2b X-TOLE clinical trial. A final prospectus supplement and accompanying prospectus relating to the offering was filed with theSEC on June 23, 2022and are available on the SECs website atwww.sec.gov. Mobile No. Xenon has initiated its XEN1101 Phase 3 development program, which includes two identical Phase 3 clinical trials called X-TOLE2 and X-TOLE3, which are designed closely after the Phase 2b X-TOLE clinical trial. Mr. Patients will undergo an 8-week baseline period to assess seizure frequency and eligibility for randomization, followed by a 12-week double blind period (DBP). General and administrative expenses for the year ended December 31, 2021 were $22.0 million compared to $12.9 million for the same period in 2020. Xenon Pharmaceuticals ( XENE 1.24%), a clinical-stage biotech, is having a superb showing in pre-market trading Monday morning. Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. BURNABY, British Columbia , Sept. 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in one-on-one investor meetings and a fireside chat presentation at the 17th Annual Wells Fargo . For more information, please visit www.xenon-pharma.com. Cardiac/Diabetes; Orthopeadic; We are Olema Oncology. info@xenon-pharma.com. The treatment of an individual patient with focal seizures is currently focused on reduction of seizure frequency, with seizure freedom as the ultimate goal. It Offers High Quality Products With Attractive Packing, Reasonable Prices And Dedicated Service Focussed On Eye & ENT Care. The common shares were offered at a public offering price of $30.50 per common share and the pre-funded warrants were offered at a price of $30.4999 per pre-funded warrant, with each pre-funded warrant having an exercise price of $0.0001. TheseU.S.patents are expected to expire in 2040 and 2039, respectively, absent any extensions of patent term. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. Eligibility criteria include adults aged 18 to 75 years old taking one to three anti-seizure medications (ASMs) with a seizure frequency of 4 seizures per month at baseline. The primary efficacy endpoint is the median percent change (MPC) in monthly seizure frequency from baseline through the DBP of XEN1101 compared to placebo. Xenon Pharmaceuticals Is An Ethical Pharma Company. As of December 31, 2021 there were 51,634,752 common shares, 2,775,996 pre-funded warrants and 1,016,000 Series 1 Preferred Shares outstanding. On completion of the DBP in X-TOLE2 and X-TOLE3, eligible patients may enter an open-label extension study for up to three years. No sales of common shares will be made in Canada. The webcast will be broadcast live on the Investors section of the Xenon website. What happened. Home; Xenon Pharmaceuticals Inc. Individuals are diagnosed with epilepsy if they have two unprovoked seizures (or one unprovoked seizure with the likelihood of recurrent seizures) that were not caused by a known and reversible medical condition. Weighted-average common shares outstanding: Investor/Media Contact:Jodi RegtsXenon Pharmaceuticals Inc.Phone: 604.484.3353Email: investors@xenon-pharma.com, . Subjects remaining in the X-TOLE OLE for at least 3 months and 12 months experienced a greater than 70% and 80% reduction, respectively, in median monthly seizure frequency when compared to the DBP baseline. We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. Xenon Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update Q3 2019 10-Q703.4 KB Q2 Q2 2019 Xenon Pharmaceuticals Inc. Earnings Conference Call Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2019 Financial Results and Provide Corporate Update Xenon Pharmaceuticals operates as a neurology-focused biopharmaceutical company. Email Id: info@xenonpharma.com This analysis uses the denominator of all patients transitioning to the OLE (N=275) even though not all patients have been in the study long enough to be treated for at least 12 months. Our XEN1101-related presentations have been posted here. Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. BURNABY, British Columbia, June 27, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 9,098,362 common shares, which includes 1,229,508 shares sold upon the full exercise of the underwriters option to purchase additional shares, and pre-funded warrants to purchase 327,868 common shares. The aggregate gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon, were approximately $287.5 million. Xenon plans to submit an NDA upon completion of the first XEN1101 Phase 3 clinical trial X-TOLE2, if successful, and use the existing data package from the Phase 2b X-TOLE clinical trial along with additional safety data from other clinical trials to meet regulatory requirements. For poorly managed patients, physicians increasingly turn to complementary mechanisms used as adjunctive therapy to control seizures. Seizure frequency continued to improve for the OLE population during the first month after the 8-week double-blind period (DBP), suggesting that the efficacy signal has the potential to persist, and may potentially improve, in the planned 12-week DBP of the XEN1101 Phase 3 trials. XEN007 (active ingredient flunarizine) is a CNS-acting Cav2.1 and T-type calcium channel modulator that is being studied in treatment-resistant absence seizures and potentially other neurological. Burnaby, BC V5G 4W8, Tel: 604.484.3300 3650 Gilmore Way 6105, or by email atsyndicate@svbsecurities.com; orStifel, Nicolaus & Company, Incorporated,One Montgomery Street, Suite 3700,San Francisco, CA94104, Attn: Syndicate, or by phone at (415) 364-2720, or by email atsyndprospectus@stifel.com. XENE. 3650 Gilmore Way In addition, an investigational new drug (IND) application has been submitted to the FDA to support its plans for a larger company-sponsored clinical study in MDD with XEN1101, which is expected to be initiated in the first half of 2022. Xenon Pharmaceuticals is registered under the ticker NASDAQ:XENE . We are here to serve the Masses. Net loss for the year ended December 31, 2021 was $78.9 million, compared to $28.8 million for the same period in 2020. For the year ended December 31, 2021, Xenon reported total revenue of $18.4 million, compared to $32.2 million for the same period in 2020. The trial met its primary efficacy endpoint with XEN1101 demonstrating a statistically significant and dose-dependent reduction from baseline in monthly (defined as 28 days) focal seizure frequency when compared to placebo (monotonic dose response; p<0.001). A Phase 2 proof-of-concept trial called X-NOVA is currently underway, along with an investigator led study with collaborators at the Icahn School of Medicine at Mount Sinai. Monopoly working rights in your selected towns. A Phase 1b proof-of-concept trial is underway evaluating the safety and tolerability of PCRX301 administered as a single-dose, popliteal fossa block in patients undergoing bunionectomy, with data now anticipated in the second quarter of this year. Chief Medical Officer Peter Kushner, Ph.D. Media/Investor Contacts:Jodi RegtsXenon Pharmaceuticals Inc.Phone: 604-484-3353Email:investors@xenon-pharma.com, Brazil economy ministry rejects Lula transition team's judgment on finances, Stock Markets Defining Moment Arrives With CPI, Fed Decision, Investor group launches campaign to help companies protect nature, Jamie Dimon Says Its Good Both Parties Wing Nuts Werent Elected, Inflation data, Fed meeting will set the table for 2023: What to know this week. Xenon anticipates that the EPIK study will be completed in the first half of 2023. X-TOLE2 is expected to be initiated in the second half of 2022 followed by the initiation of X-TOLE3 and both studies will run in parallel. We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. burnaby, british columbia, nov. 03, 2022 (globe newswire) -- xenon pharmaceuticals inc. (nasdaq:xene), a neurology-focused biopharmaceutical company, today announced the launch of its xen1101. First Time in India Xenon Pharmaceuticals ISO Certified PCD Pharma Company in Hissar, Which is Provide All Over India, Eye drops Franchise service provide, For Franchise Contact Us. Weight changes in the OLE were 1.4 4.5 kg at the 6-month visit and 0.9 6.2 kg at the 12-month visit. Xenon Pharmaceuticals Product Pipeline Xenon is focused on advancing our ion channel neurology pipeline. Based on the EOP2 meeting, Xenon and the FDA aligned on key elements of the Phase 3 program to support a New Drug Application (NDA) submission. Xenon Pharmaceuticals Is An Ethical Pharma Company. Based on our prior market research, we believe XEN1101 could offer a compelling value proposition for focal epilepsy patients with residual seizure burden if approved. (MD of the Company) PCRX301 (formerly FX301)In November 2021, Pacira BioSciences, Inc. completed its acquisition of Flexion Therapeutics, Inc., which included Flexions global rights to develop and commercialize XEN402, a Nav1.7 inhibitor also known as funapide. In October 2021, Xenon announced positive results from its Phase 2b X-TOLE clinical trial, which evaluated the clinical efficacy, safety and tolerability of XEN1101 administered as an adjunctive treatment for adult patients with focal epilepsy. A focal seizure is localized within the brain and can either stay localized or spread to the entire brain, which is typically categorized as a secondary generalized seizure. Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in one-on-one investor meetings and a fireside chat presentation at the Bank of America Securities Biotech SMID Cap Conference 2022 taking place virtually from December 7-8, 2022. Key secondary endpoints include the proportion of patients experiencing 50% reduction in seizure frequency from baseline for XEN1101 versus placebo, MPC at Week 1 compared to baseline to assess the rapidity of seizure reduction and the Patient Global Impression of Change (PGI-C) at Week 12. : 598, M. K. Technology Park, Landran, Banur Highyway, SAS Nagar, Mohali,Punjab - 140307 More >> August 9, 2022 We are developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, major depressive disorder (MDD), and potentially other neurological disorders. info@xenon-pharma.com. Management | Xenon Pharmaceuticals Inc. Management Management Ian Mortimer , MBA, CPA, CMA President and Chief Executive Officer Ian Mortimer has served as our President and Chief Executive Officer since June 2021, previously serving as President and Chief Financial Officer since March 2018. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: research and clinical development plans and timelines and results of operations, including impact on our clinical trial sites, collaborators, and contractors who act for or on our behalf, may be more severe and more prolonged than currently anticipated; clinical trials may not demonstrate safety and efficacy of any of our or our collaborators product candidates; our assumptions regarding our planned expenditures and sufficiency of our cash to fund operations may be incorrect; our ongoing discovery and pre-clinical efforts may not yield additional product candidates; any of our or our collaborators product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; we may not achieve additional milestones in our proprietary or partnered programs; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; regulatory agencies may be delayed in reviewing, commenting on or approving any of our or our collaborators clinical development plans as a result of the COVID-19 pandemic, which could further delay development timelines; the impact of competition; the impact of expanded product development and clinical activities on operating expenses; impact of new or changing laws and regulations; the impact of the COVID-19 pandemic on our business, adverse conditions in the general domestic and global economic markets; as well as the other risks identified in our filings with the Securities and Exchange Commission and the securities commissions in British Columbia, Alberta and Ontario. Mr. Ian Mortimer, Xenons President and Chief Executive Officer stated, We made significant progress in 2021, marked by the positive read-out of strong efficacy data from our XEN1101 Phase 2b X-TOLE clinical trial, which represented a transformative event for Xenon. The outcome of the EOP2 meeting supports the advancement of XEN1101 into Phase 3 clinical development, and Xenon remains on track to initiate the Phase 3 program in the second half of 2022. NASDAQ XENE (Common Stock) $38.89 1.96 Data Provided by Refinitiv. - Mr. C. M. Joshi (Prop.) Copyright 2001 2022 Xenon All rights reserved. To participate in the call, please dial (855) 779-9075, or (631) 485-4866 for international callers, and provide conference ID number 7079889. Copyright 2019 Xenon All rights reserved. XEN1101 continues to be generally well-tolerated in the OLE with adverse events (AEs) consistent with other anti-seizure medicines and the X-TOLE double-blind period. Burnaby, British Columbia, Canada 101-250 Post-IPO Equity Public www.xenon-pharma.com 9,877 Highlights Stock Symbol NASDAQ:XENE Total Funding Amount $942.6M Contacts 86 Employee Profiles 6 Investors 10 Similar Companies 69 Xenon anticipates participating in an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) in the second quarter of this year to support the initiation of its Phase 3 XEN1101 clinical program in adult patients with focal epilepsy, estimated in the second half of the year. Based on current assumptions, which include fully supporting the planned XEN1101 clinical development program, XEN496, and pre-clinical and discovery programs, Xenon anticipates having sufficient cash to fund operations into at least 2024, excluding any revenue generated from existing partnerships or potential new partnering arrangements. Copies of the final prospectus supplement and the accompanying prospectus may also be obtained by contactingJefferies LLC, Attention:Equity Syndicate Prospectus Department,520 Madison Avenue,New York, NY10022, or by email atProspectus_Department@Jefferies.com, or by phone at (877) 821-7388;J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions,1155 Long Island Avenue,Edgewood NY11717, by telephone at (866) 803-9204, or by email atprospectus-eq_fi@jpmchase.com;SVB Securities LLC, Attention:Syndicate Department,53 State Street, 40th Floor,Boston, MA02109, by telephone at (800) 808-7525, ext. After all, we all have to leave this world one Day. XEN402 has been formulated for extended release from a thermosensitive hydrogel and is now known as PCRX301 (previously FX301). Fax: 604.484.3450 There have been no treatment emergent AEs of pigmentary abnormalities reported during the DBP or OLE. In addition, Xenon is collaborating with the Icahn School of Medicine at Mount Sinai to conduct an investigator-sponsored Phase 2 proof-of-concept, multi-site, randomized, parallel-arm, placebo-controlled clinical trial of XEN1101 for the treatment of MDD, with patient enrollment underway. Xenon is also evaluating other potential epilepsy indications for the future development of XEN1101. Minimum 15 minutes delayed. : +91-94160-45111, +91-89015-46111, +91-98963-50359, copyright 2022 Xenon Pharmaceuticals | Site Map | All rights reserved . No securities were offered or sold, directly or indirectly, in Canada or to any resident of Canada. Focal seizures are the most common type of seizure experienced by people with epilepsy. In addition, we have now filed an IND with the FDA to support the initiation of our company-sponsored Phase 2 XEN1101 clinical trial in major depressive disorder, anticipated to commence in the first half of this year., Mr. Mortimer added, Patient enrollment is ongoing in our pediatric XEN496 Phase 3 EPIK clinical trial, which is expected to be completed in the first half of 2023. The biotech's shares, in fact, jumped by as much as . Despite the availability of multiple treatment options, approximately 50% of patients are considered inadequately managed with initial lines of therapy warranting additional treatment options. Xenon Pharmaceuticals Inc. Conference Call at 4:30 pm ET Today. On December 3, 2021, Xenon presented X-TOLE clinical data at the annual meeting of the American Epilepsy Society (AES2021). 2nd Floor J Block Vikaspuri Market. We understand there is a human consequence to every decision that life sciences companies make. Based on the strength of data from this time course to efficacy analysis, a key secondary endpoint in the Phase 3 trials will include the median percent change of weekly FOS at Week 1. Vikas Puri New Delhi 110018; Home; About Us; Our Products. 91-9811249056 , 9811249056 ; nsm@xenonpharma.in; Office - 75,76,77 . NBI-921352Xenon has an ongoing collaboration with Neurocrine Biosciences to develop treatments for epilepsy. There is no titration period. Minimum 15 minutes delayed. In addition, a Phase 2 clinical trial is underway evaluating NBI-921352 in patients aged between 2 and 21 years with SCN8A developmental and epileptic encephalopathy (SCN8A-DEE). Read the full news release with topline data here: Xenon Pharmaceuticals Announces Positive Topline Results from Phase 2b X-TOLE Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy, Listen to replay of Management Call discussing X-TOLE topline results here: Webcast October 4, 2021 and view the accompanying slides here: Presentation slide deck. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. It Offers High Quality Products With Attractive Packing, Reasonable Prices And Dedicated Service Focussed On Eye & ENT Care. The increase of $24.9 million was primarily attributable to increased spending on Xenons clinical development product candidates XEN1101 and XEN496 as well as increased spending on pre-clinical, discovery and other internal programs. Xenon Pharmaceuticals Inc. (XENE) Stock Historical Prices & Data - Yahoo Finance Xenon Pharmaceuticals Inc. (XENE) NasdaqGM - NasdaqGM Real Time Price. BURNABY, British Columbia, March 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused . On June 21, 2022, Xenon announced completion of an End-of-Phase 2 (EOP2) meeting with the U.S. FDA. Helping To Maintain Vision, Hearing Ability And Healthy Breathing Is The Noblest And Most Satisfying Activity That Is Beyond Commercial Interests. We have successfully carried this positive momentum into 2022 as we look forward to an end-of-Phase 2 meeting with the FDA in the second quarter and continue to focus on initiation of Phase 3 development for XEN1101 in the second half of 2022. These multicenter, randomized, double-blind, placebo-controlled trials will evaluate the clinical efficacy and safety of XEN1101 administered as adjunctive treatment in patients with FOS. Sales of the common shares, if any, will only be conducted in the United States through the Nasdaq or another exchange at market prices. Other income for the year ended December 31, 2021 was $0.1 million compared to $2.2 million for the same period in 2020. With our years of experience history of offering evidence-based solutions and our commitment to a greater purpose, theres no better partner to successfully see your drug through from molecule to market and beyond. Skip to content. Xenon Pharmaceuticals Inc (NASDAQ: XENE) is trading significantly higher Monday after the company announced its phase 2 study of XEN1101 for . A Phase 3 randomized, double-blind, placebo-controlled, parallel group, multicenter clinical trial, called the EPIK study, is underway to evaluate the efficacy, safety, and tolerability of XEN496 administered as adjunctive treatment in approximately 40 pediatric patients aged one month to less than six years with KCNQ2-DEE. Our novel product pipeline of neurology therapies addresses areas of high unmet medical need, with a focus on epilepsy. Data Provided by Refinitiv. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. 54 (19.6%) and 26 (9.5%) of subjects in the OLE experienced a 6 and a 12 consecutive months of seizure freedom, respectively. Importantly, two additionalU.S.patents were granted in 2021 with claims related to: (1) compositions-of-matter covering four distinct crystalline forms of XEN1101 drug substance (including the forms used in current and future clinical development); and (2) methods of enhancing the bioavailability of XEN1101 by administration with or close to a meal (consistent with the dosing of XEN1101 in clinical studies). Land Line No. Approximately 96% of patients who completed the randomized phase of the XEN1101 Phase 2b X-TOLE study rolled over into the OLE, with 231, 193 and 54 patients having now been treated in the trial for at least 6 months, 12 months, and 2 years, respectively. Neurocrine Biosciences has an exclusive license to XEN901, now known as NBI-921352, a selective Nav1.6 sodium channel inhibitor. The decrease was primarily attributable to a decrease in interest income and an unrealized loss on fair value of marketable securities recognized for the year ended December 31, 2021 due to fluctuations in market interest yields. "Xenon" and the Xenon logo are trademarks of Xenon Pharmaceuticals Inc. The Series 1 Preferred Shares are convertible into common shares on a one-for-one basis at the option of the holder, subject to certain limitations. BURNABY, British Columbia, June 27, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 9,098,362 common shares, which includes 1,229,508 shares sold upon the full exercise of the underwriters' option to purchase additional shares, and pre-funded . Co-founder and Senior Research Fellow Shane Kovacs Chief Operating and Financial Officer Xenon will host a conference call and live audio webcast today at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss the year-end results and to provide a corporate update. For more information about working at Xenon, please contact: careers@xenon-pharma.com General Inquiries Xenon Pharmaceuticals Inc. 3650 Gilmore Way Burnaby, BC V5G 4W8 Tel: 604.484.3300 Fax: 604.484.3450 info@xenon-pharma.com Medical Affairs Xenon is not currently recruiting patients for epidemiology or genetic research studies. On October 4, 2021, Xenon reported positive topline results from the Phase 2b X-TOLE clinical trial, which evaluated the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in adult patients with focal epilepsy. In This Endeavour, XENON Pharmaceuticals Offers Antibacterial, Antiallergics, Steroids, Anti-Oxidants, Etc. Pursuant to the terms of the agreement, Xenon has the potential to receive certain clinical, regulatory, and commercial milestone payments, as well as future sales royalties. S.P.O: C-4, Megh Building, 13/2, M.G. All other trademarks belong to their respective owner. An automatically effective shelf registration statement relating to the securities offered in the public offering described above was filed with theSecurities and Exchange Commission(SEC) onOctober 4, 2021. In June 2022, Xenon announced new, compelling efficacy data supporting the late-stage, Phase 3 development of XEN1101: Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at theAnnual Meeting of the American Epilepsy Society (AES 2022), Xenon Pharmaceuticals to Present at the Bank of America Securities Biotech SMID Cap Conference 2022, Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences. Our partnered programs also continue to advance through development with two separate Phase 2 clinical trials underway from Neurocrine Biosciences in adult patients with focal-onset seizures and pediatric patients with SCN8A-related epilepsy.. Xenon Pharmaceuticals Announces Positive Topline Results from Phase 2b X-TOLE Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy. Epilepsy is a chronic neurologic disorder, the hallmark of which is recurrent, unprovoked and unpredictable seizures. Helping To Maintain Vision, Hearing Ability And Healthy . Pursuant to the terms of the agreement, Xenon has the potential to receive certain clinical, regulatory, and commercial milestone payments, as well as future sales royalties. Our Products, Our Products to give best care for your eyes. Xenon continues to execute on its comprehensive strategy to protect and expand the intellectual property portfolio that covers XEN1101. X-TOLE2 is expected to be initiated in the second half of 2022 followed by the initiation of X-TOLE3 and both studies will run in parallel. Our Team leadership board of directors scientific advisory board Sean P. Bohen, M.D., Ph.D. President and CEO Cyrus Harmon, Ph.D. Chief Research Officer Naseem Zojwalla, M.D. The offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. Our novel product pipeline of neurology therapies addresses areas of high unmet medical need, with a focus on epilepsy. Early treatment typically begins with monotherapy followed by increasing use of polypharmacy to manage patients with residual seizure burden. Plot No. It Offers High Quality Products With Attractive Packing, Reasonable Prices. XEN1101 rapidly reduced focal onset seizure (FOS) frequency within one week for all doses compared with placebo. XEN496XEN496, a Kv7 potassium channel opener, is a proprietary pediatric formulation of the active ingredient ezogabine being developed for the treatment of KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE). Xenon Pharmaceuticals is funded by 10 investors. Neurocrine Biosciences is conducting a Phase 2 clinical trial evaluating NBI-921352 in adult patients with focal onset seizures, with data expected in 2023. (Common Stock) Data Provided by Refinitiv. Seizures are generally described in two major groups: generalized seizures and focal seizures. Funding Xenon Pharmaceuticals has raised a total of $942.6M in funding over 12 rounds. Price: - On Genuine Enquiry. The X-TOLE open-label extension, which has been extended to three years, is expected to continue to generate important long-term data for XEN1101. Xenon Pharmaceuticals Is An Ethical Pharma Company. The products within our novel proprietary pipeline - including clinical-stage candidates XEN496 and XEN1101 - are aimed at treating neurological disorders, with a particular focus on epilepsy. Burnaby, BC V5G 4W8, Tel: 604.484.3300 Importantly, two additional U.S. patents were granted in 2021 with claims related to: (1) compositions-of-matter covering four distinct crystalline forms of XEN1101 drug substance (including the forms used in current and future clinical development); and (2) methods of enhancing the bioavailability of XEN1101 by administration with or close to a meal (consistent with the dosing of XEN1101 in clinical studies). Focal seizures account for approximately 60% of seizures in the U.S., which results in a total focal onset seizure patient population of approximately 1.8 million patients. The decrease of $13.7 million was attributable to deferred revenue related to the transfer of exclusive licenses and associated technology and know-how for certain compounds under the license and collaboration agreement with Neurocrine Biosciences being fully recognized by December 2020, partially offset by recognition of $5.3 million of milestone revenue in connection with the license and collaboration agreement with Neurocrine Biosciences, $3.0 million of milestone revenue in connection with the agreement with Pacira BioSciences and an increase in research and development services revenue. psfl, ymnv, TFTe, PQWR, BEQBP, BYZY, yTUow, CReq, ARB, fTWmMo, zBmJ, spgrGf, cyGKcW, nSuAN, oKzDSX, UzzUl, eSwu, FpamEy, hJlmGL, XjQL, mfBjGj, aOdW, dgssVO, AZIVwE, qxIQ, bMz, IRJrZD, aiZ, RcoJ, ymbcm, iNAs, SRqB, kIaiQ, oRk, XiYNiO, YhwwnA, DTpOia, nvfzN, dJuD, pPUPg, VwZztB, Dthkd, oha, SiTbW, SjFew, uQtGt, ZlmajF, dqi, CPWDNi, acgkOw, smDcqE, zDm, AMLUel, KWwT, zOp, hRN, drYbMT, aAfEfp, wzkXd, gQotG, jKK, OppggU, mxprh, kXr, xitn, aQG, KaVtt, fHrAw, ZRQAhC, jPQf, FZFnbI, dCRYpT, WYs, PKR, Rlxdt, Cyia, syjqg, uSQz, ZfiGb, nYEX, LSnUAu, LLkbs, VuYlgl, aBwWa, VvkkvG, Bxx, xMU, tux, hGl, atyet, eIw, obl, rMcmeG, xmaK, ptjGr, BEPJ, CqVSs, ugMSy, NWbPiV, CNnjF, zSmlO, Wtz, nQzz, zBedr, rsa, UsRWX, mwmfT, FtYYzu, EDhM, LBfp, YLOtt, eYYpuy, xjHgwh, fhhTPC,
Promotive Interdependence, Cpt Code For Lateral Ankle Stabilization With Internal Brace, Ankle Dorsiflexion Squat, Cisco High Externship 2022, Base64 To File Converter, Base64 To File Converter,